Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0432222 (SEM)
 47,337 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty-six patients with the gastrinoma syndrome were divided into 2 categories: 1) benign sporadic gastrinoma (n = 30), and 2) gastrinoma with metastases to liver (n = 16). Thirteen of the 46 patients had multiple endocrine neoplasia type I syndrome. Serum gastrin levels in patients fasted overnight were determined by RIA using antisera directed toward the NH2- and COOH-terminals of heptadecapeptide gastrin (G17) and the NH2-terminus of the triacontatetrapeptide (G34). These results were compared with findings in 50 normal subjects. In the normal subjects, the mean COOH-terminal gastrin-17 level was higher [65 +/- 8 (+/- SEM) pg/ml] than the NH2-terminal gastrin-17 level (11 +/- 0.2 pg/ml) and lower than the NH2-terminal gastrin-34 level (134 +/- 20 pg/ml). The levels of NH2-terminal gastrin-17 were higher in patients with metastatic disease than in those with benign gastrinoma, whereas the COOH-terminal gastrin-17 and the NH2-terminal gastrin-34 levels were similarly high in both groups. The mean ratio of NH2-terminal gastrin-17 to COOH-terminal gastrin-17 was less than 1 in normal subjects (0.22 +/- 0.02) and benign gastrinoma patients (0.2 +/- 0.04), and it was 2.2 +/- 0.41 in the patients with metastatic gastrinoma. An NH2 to COOH gastrin-17 ratio greater than 1 was found in 13 of 16 patients with metastatic gastrinoma, but in none of the patients with benign gastrinoma or normal subjects. Similar results were found in multiple endocrine neoplasia type I patients with benign and metastatic disease. A high NH2 to COOH gastrin-17 ratio is suggestive of metastatic gastrinoma. In 4 patients with metastatic gastrinoma, the NH2 to COOH gastrin-17 ratio fell in parallel with the response to chemotherapy.
 ...
PMID:Evaluation of NH2-terminus gastrins in gastrinoma syndrome. 287 76

This study was designed to examine and compare the nature of gastrinlike and cholecystokininlike peptides released into the portal and peripheral venous circulation in response to a peptone meal. Six dogs were prepared with portal venous catheters and gastric fistulas. Portal and peripheral venous sera were obtained before and after gastric infusion of a 10% peptone meal. Serum levels of gastrin and cholecystokinin immunoreactive peptides were determined by radioimmunoassay using two distinct peptide region-specific antibody preparations. These separate antibody preparations demonstrated specificity for (a) C-terminal tetradecapeptide gastrin (4-17hG17), heptadecapeptide gastrin (G17), and big gastrin (G34) (gastrin antibody); and (b) all biologically active forms of gastrin and cholecystokinin (gastrin-cholecystokinin antibody). Using the antibody preparation with specificity for gastrin and not cholecystokinin, the mean basal immunoreactive gastrin from portal (8.33 +/- 2.4 fmol/ml, mean +/- SEM) and from peripheral (6.19 +/- 0.9 fmol/ml) venous sera both increased after peptone infusion, with an early peak (2 min in portal and 4 min in peripheral serum) and a second peak at 30 min in both circulations. Measurements using antibodies with specificity for both cholecystokinin and gastrin yielded strikingly different results. The portal venous serum peptide concentration (49 +/- 10 fmol/ml) increased sharply within 30 s after peptone infusion to a single peak at 2 min (139 +/- 37 fmol/ml). The basal peripheral venous serum peptide concentration (43 +/- 8.8 fmol/ml) increased more gradually to a single peak at 8 min (78 +/- 14 fmol/ml). Studies with Sephadex (G-50 superfine) gel chromatography indicated that gastrin released in response to the peptone meal was primarily G17. However, of the peptides released in response to the peptone meal that were recognized by the gastrin-cholecystokinin antibody, greater than 80% were shown to be distinct from gastrin. Gel chromatographic studies demonstrated that peptone meal-stimulated immunoreactive cholecystokinin release consisted of two major peaks, eluting in positions identical to those of intact cholecystokinin (CCK33) and the octapeptide of cholecystokinin (CCK8).
 ...
PMID:Immunochemical characterization of gastrinlike and cholecystokininlike peptides released in dogs in response to a peptone meal. 620 7

Seven Sprague-Dawley rats (404-440 g) underwent a 90% jejuno-ileal bypass (JIB); the functional loop consisted of 1/3 ileum and 2/3 jejunum with the bypassed loop being anastomosed to the ascending colon. Seven control rats were sham-operated. After 35 days, the rats were fasted 18 hours and venous blood was collected. Immunoreactivity of gastrin, measured with an antibody binding equally to G17 and G34, was higher in the plasma of the JIB (256 +/- 55 SEM pg/ml) than control (85 +/- 9 pg/ml) rats. This agrees with recent human studies but is in conflict with results in less mature rats. VIP levels were not significantly different. Glucagon-like immunoreactivity measured with antibodies specific for the C- and N-terminal regions of the hormone, respectively, were also higher in the JIB (510 +/- 40 and 129 +/- 15 pg/ml) rats.
 ...
PMID:Circulating immunoreactivities of gastrin, glucagon and VIP after jejuno-ileal bypass. 707 93